Pfizer, Astellas Execs Talk Deals At BIO Asia
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Although the economic slump may seem like an opportune time for more mergers and acquisitions with big pharmas taking over biotechs, there are challenges to such an approach, pharma executives told attendees of the annual BIO Asia partnering conference Jan. 19